Abstract
The cholinergic hypothesis of Alzheimers disease has spurred the development of numerous structural classes of compounds with different pharmacological profiles aimed at increasing central cholinergic neurotransmission, thus providing a symptomatic treatment for this disease. Indeed, the only drugs currently approved for the treatment of Alzheimers disease are cholinomimetics with the pharmacological profile of acetylcholinesterase inhibitors. Recent evidence of a potential disease modifying role of acetylcholinesterase inhibitors and M1 muscarinic agonists have led to a revival of this approach, which might be considered as more than a symptomatic treatment.
Keywords: Cholinergic Drugs, Alzheimers disease, muscarinic agonists, acetylcholine (ACh), Potassium Channel Blockers, Aminoacridines, N-Benzylpiperidines, xanomeline, muscarine
Mini-Reviews in Medicinal Chemistry
Title: Cholinergic Drugs in Pharmacotherapy of Alzheimers Disease
Volume: 2 Issue: 1
Author(s): Pelayo Camps and Diego Munoz-Torrero
Affiliation:
Keywords: Cholinergic Drugs, Alzheimers disease, muscarinic agonists, acetylcholine (ACh), Potassium Channel Blockers, Aminoacridines, N-Benzylpiperidines, xanomeline, muscarine
Abstract: The cholinergic hypothesis of Alzheimers disease has spurred the development of numerous structural classes of compounds with different pharmacological profiles aimed at increasing central cholinergic neurotransmission, thus providing a symptomatic treatment for this disease. Indeed, the only drugs currently approved for the treatment of Alzheimers disease are cholinomimetics with the pharmacological profile of acetylcholinesterase inhibitors. Recent evidence of a potential disease modifying role of acetylcholinesterase inhibitors and M1 muscarinic agonists have led to a revival of this approach, which might be considered as more than a symptomatic treatment.
Export Options
About this article
Cite this article as:
Camps Pelayo and Munoz-Torrero Diego, Cholinergic Drugs in Pharmacotherapy of Alzheimers Disease, Mini-Reviews in Medicinal Chemistry 2002; 2 (1) . https://dx.doi.org/10.2174/1389557023406638
DOI https://dx.doi.org/10.2174/1389557023406638 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Overview of Neolignans of the Genus Piper L.: Isolation Methods and Biological Activities
Mini-Reviews in Medicinal Chemistry Identification of Novel Phyto-chemicals from Ocimum basilicum for the Treatment of Parkinson’s Disease using In Silico Approach
Current Computer-Aided Drug Design Emerging Targets in Neurodegeneration: New Opportunities for Alzheimer's Disease Treatment?
Current Topics in Medicinal Chemistry Introduction to the Special Issue “Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence” and a Summary of Patents Targeting other Neurotransmitter Systems
Recent Patents on CNS Drug Discovery (Discontinued) Current Insights for the Management of Acne in the Modern Era
Recent Patents on Anti-Infective Drug Discovery Chinese Character Voice Processing of the Bilateral Inferior Parietal Lobule of Literate Compared with Illiterate Subjects: An fMRI Study
Neuroscience and Biomedical Engineering (Discontinued) Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: α7-nAChR Agonists in Human Clinical Trials
Current Pharmaceutical Design Towards the Management of Inflammation: Recent Developments of mPGES-1 Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Antioxidant Activity of Resveratrol Analogs
Letters in Drug Design & Discovery Voltage-gated Sodium Channels in Sensory Information Processing
CNS & Neurological Disorders - Drug Targets What Affects Body Size Estimation? The Role of Eating Disorders,Obesity, Weight Loss, Hunger, Restrained Eating, Mood, Depression,Sexual Abuse, Menstrual Cycle, Media Influences, and Gender
Current Psychiatry Reviews Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Current Medicinal Chemistry Social Network Analysis of Dementia Wards in Psychiatric Hospitals to Explore the Advancement of Personhood in Patients with Alzheimer’s Disease
Current Alzheimer Research CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry The Possible Involvement of HLA Class III Haplotype (RAGE, HSP70 and TNF Genes) in Alzheimer's Disease
Current Alzheimer Research Common Molecular Targets for Bioactive Food Components and Drugs
Current Pediatric Reviews Neurochemical Changes in the Brain After Fetal Exposure to Fluoxetine, A Serotonin Reuptake Inhibitor (SRI) in Rodents
Current Proteomics Tacrine Derivatives and Alzheimers Disease
Current Medicinal Chemistry Oligomeric Amyloid β -Protein as a Therapeutic Target in Alzheimers Disease: Its Significance Based on its Distinct Localization and the Occurrence of a Familial Variant Form
Current Alzheimer Research